1,024 material Form 8-K filings that 799 companies we cover made with the SEC in August 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Coinbase completed a private offering of $1.5 billion of 0% convertible senior notes due 2029 and $1.5 billion due 2032, including the full exercise of initial purchasers' options for an additional $200.0 million of each series. Holders can convert into cash, Class A common stock, or a combination, at the company's election, so conversions could affect existing shareholders' ownership if the company settles in shares.
$1.5 billion of 0% convertible senior notes due October 1, 2029, with an initial conversion price of about $454.44 per share
$1.5 billion of 0% convertible senior notes due October 1, 2032, with an initial conversion price of about $394.84 per share
Conversion prices carry premiums of about 52.5% (2029 notes) and 32.5% (2032 notes) to the $297.99 closing price on August 5, 2025
The notes are senior unsecured obligations; U.S. Bank Trust Company, National Association is the trustee
Centrus Energy's chief financial officer, Kevin Harrill, resigned on August 7, 2025, to pursue other opportunities, and the board appointed Todd Tinelli to succeed him effective August 11, 2025. Harrill will stay in an advisory role until August 29, 2025, and the company says the departure is not due to any disagreement over operations, policies or practices.
Kevin Harrill resigned as SVP, CFO and Treasurer, effective August 10, 2025, and will advise through August 29, 2025
Todd Tinelli, 45, becomes SVP, CFO and Treasurer effective August 11, 2025; previously CFO and COO of Hartree Partners and Sprague Resources
Tinelli's compensation includes a $425,000 base salary, up to $125,000 relocation benefits, an 80% bonus target, and equity awards of $100,000 stock and $300,000 RSUs
Tinelli must obtain and maintain a DOE "Q" security clearance within 18 months
Koppers reported second quarter 2025 sales of $504.8 million, down from $563.2 million a year earlier, and GAAP diluted EPS of $0.81 versus $1.25. The company cut its 2025 forecast, lowering its sales outlook to $1.9 billion to $2.0 billion from $2.0 billion to $2.2 billion and its adjusted EBITDA outlook to $250 million to $270 million, because it expects continued lower demand. Adjusted EPS rose to $1.48 from $1.36, but the lower sales and guidance cut weigh on the outlook for shareholders.
Q2 2025 net sales were $504.8 million, down 10.4% from $563.2 million; GAAP diluted EPS was $0.81 versus $1.25
Adjusted EPS was $1.48 versus $1.36 a year earlier; adjusted EBITDA was $77.1 million versus $77.5 million
2025 guidance revised: sales of $1.9 billion to $2.0 billion (previously $2.0 billion to $2.2 billion) and adjusted EBITDA of $250 million to $270 million
Adjusted EPS guidance is $4.00 to $4.60; operating cash flow projection of $150 million was maintained
AAM (NYSE: AXL) reported second-quarter 2025 sales of $1.54 billion, down from $1.63 billion a year earlier, while net income rose to $39.3 million from $18.2 million. The filing says the net income increase reflects a $46.3 million gain on its Business Combination Derivative, while Adjusted EBITDA fell to $202.2 million from $208.4 million, and the company raised the low end of several full-year 2025 targets.
Sales were $1.54 billion versus $1.63 billion a year earlier, which the company attributed to lower volume and mix.
Diluted EPS was $0.32 versus $0.15; Adjusted EPS was $0.21 versus $0.19. Adjusted EBITDA margin was 13.2% versus 12.8%.
Full-year 2025 targets: Adjusted EBITDA $695 million to $745 million (previously $665 million to $745 million); sales $5.75 billion to $5.95 billion (previously $5.65 billion to $5.95 billion).
CEO David C. Dauch said shareholders of both companies approved the combination with Dowlais.
Sotera Health reported second-quarter 2025 net revenues up 6.4% to $294 million and Adjusted EBITDA up 9.8% to $151 million, and raised its full-year 2025 outlook for revenue, Adjusted EBITDA and Adjusted EPS. GAAP net income was $8 million, or $0.03 per diluted share, slightly below $9 million a year earlier, and includes a pending settlement of about $34 million related to ethylene oxide claims against Sterigenics.
Q2 2025 net revenues rose 6.4% to $294 million; Adjusted EBITDA rose 9.8% to $151 million
Q2 2025 net income was $8 million, or $0.03 per diluted share, versus $9 million, or $0.03, in Q2 2024
Full-year 2025 Adjusted EPS outlook raised to $0.75 to $0.82 from $0.70 to $0.76
Six-month net loss of $5 million, or $0.02 per diluted share, includes settlements related to ethylene oxide claims
Alpha Metallurgical Resources reported a second-quarter 2025 net loss of $5.0 million, or $0.38 per diluted share, narrowing from a $33.9 million loss in the first quarter but down from a $58.9 million profit a year earlier. The company lowered its 2025 cost of coal sales guidance to $101 to $107 per ton, cut its SG&A guidance, and raised its idle operations expense guidance. It also plans to restart its share repurchase program on an opportunistic basis, having refrained from buybacks for about five quarters.
Q2 2025 net loss of $5.0 million ($0.38 per diluted share) versus a $33.9 million loss in Q1 2025 and net income of $58.9 million in Q2 2024
Adjusted EBITDA of $46.1 million, up from $5.7 million in Q1 2025 and down from $116.0 million in Q2 2024
2025 cost of coal sales guidance lowered to $101 to $107 per ton from $103 to $110; SG&A guidance cut to $48 million to $54 million
Total liquidity of $556.9 million as of June 30, 2025; remaining buyback authorization of approximately $400 million
Wendy's reported second-quarter 2025 results for the quarter ended June 29, 2025. Revenue and global systemwide sales declined, while diluted earnings per share rose 7.4% to $0.29, helped by a lower share count. The company lowered its full-year 2025 adjusted EPS and adjusted EBITDA outlook, which matters to shareholders because it signals weaker expected profit for the year.
Total revenues were $560.9 million, down 1.7% from $570.7 million a year earlier; diluted EPS was $0.29, up 7.4% from $0.27.
Global systemwide sales were $3.7 billion, down 1.8%; U.S. same-restaurant sales fell 3.6%, while International systemwide sales grew 8.7%.
Full-year adjusted EPS outlook is now $0.82 to $0.89, down from $0.92 to $0.98; adjusted EBITDA outlook is now $505 million to $525 million, down from $530 million to $545 million.
The board declared a regular quarterly dividend of $0.14 per share, payable September 16, 2025, to holders of record as of September 2, 2025.
Lamar Advertising reported second-quarter 2025 net revenues of $579.3 million, up 2.5%, and net income of $155.0 million, up 12.7%. The company lowered its full-year 2025 diluted AFFO per share guidance to $8.10 to $8.20 from $8.13 to $8.28, with CEO Sean Reilly citing expected revenue growth in the second half that may be smaller than anticipated at the start of the year.
Q2 2025 net revenues were $579.3 million versus $565.3 million in Q2 2024; diluted EPS was $1.52 versus $1.34
Full-year 2025 diluted AFFO per share guidance revised to $8.10 to $8.20 from $8.13 to $8.28
Q2 2025 cash flow from operations fell $26.9 million to $229.5 million; free cash flow was $199.1 million, down 2.2%
Total liquidity was $363.0 million as of June 30, 2025
ANI Pharmaceuticals reported second-quarter 2025 net revenues of $211.4 million, up 53.1% from a year earlier, and GAAP net income available to common shareholders of $8.1 million, or $0.36 per diluted share, compared with a loss of $0.14 per share in the prior-year period. The company raised its full-year 2025 guidance for net revenues to $818 million to $843 million and adjusted non-GAAP diluted EPS to $6.98 to $7.35.
Q2 2025 net revenues were $211.4 million, up 53.1% year over year, or 37.0% on an organic basis excluding the Alimera acquisition.
Cortrophin Gel net revenues were $81.6 million, up 66.0% year over year.
GAAP diluted EPS was $0.36 versus a loss of $0.14 a year earlier; adjusted non-GAAP diluted EPS was $1.80 versus $1.02.
Full-year 2025 net revenue guidance was raised to $818 million to $843 million from $768 million to $793 million.
Atmus Filtration Technologies reported second-quarter 2025 net sales of $454 million, up 4.8% from $433 million a year earlier, and GAAP net income of $60 million, or $0.72 per diluted share, versus $0.67 a year earlier. The company raised its 2025 outlook, with adjusted earnings per share now expected at $2.40 to $2.60, although gross margin fell to 28.9% from 30.5%.
Net sales of $454 million, up 4.8% from $433 million, driven mainly by higher volume and pricing
Diluted EPS of $0.72 versus $0.67; adjusted EPS of $0.75 versus $0.71
2025 guidance raised: revenue of $1,685 million to $1,735 million and adjusted EPS of $2.40 to $2.60
Gross margin 28.9% versus 30.5%; $20 million of stock repurchased during the quarter
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.